Macrogenics (MGNX) Net Income towards Common Stockholders (2012 - 2026)
Macrogenics (MGNX) reported Net Income towards Common Stockholders of -$38.3 million for Q1 2026, up 10.27% year-over-year from -$34.8 million in Q1 2025, and down 171.31% quarter-over-quarter from -$14.1 million in Q4 2025.
Macrogenics (MGNX) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$38.3 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$38.3 million, up 10.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$71.9 million (down 25.04% YoY), and the FY2025 annual result was -$74.6 million, down 11.39% from the prior year.
- Net Income towards Common Stockholders eased to -$38.3 million in Q1 2026 per MGNX's latest filing, from -$14.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $56.3 million in Q3 2024 and troughed at -$66.6 million in Q1 2022.
- A 5-year average of -$28.0 million and a median of -$38.3 million in 2026 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 511.87% in 2023, then surged 258.61% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $12.0 million in 2022, then sank by 511.87% to -$49.4 million in 2023, then surged by 68.75% to -$15.4 million in 2024, then gained by 8.39% to -$14.1 million in 2025, then slumped by 171.31% to -$38.3 million in 2026.
- Business Quant data shows MGNX's Net Income towards Common Stockholders at -$38.3 million in Q1 2026, -$14.1 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -38.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.33 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -54.88 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -45.74 Mn |
| Mar 31, 2023 | -39.08 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -66.64 Mn |
| Dec 31, 2021 | -58.24 Mn |
| Sep 30, 2021 | -52.99 Mn |
| Jun 30, 2021 | -40.28 Mn |